PharmaBlock Sciences Nanjing Inc
SZSE:300725

Watchlist Manager
PharmaBlock Sciences Nanjing Inc Logo
PharmaBlock Sciences Nanjing Inc
SZSE:300725
Watchlist
Price: 35.76 CNY 1.02% Market Closed
Market Cap: 7.1B CNY
Have any thoughts about
PharmaBlock Sciences Nanjing Inc?
Write Note

PharmaBlock Sciences Nanjing Inc
Common Shares Outstanding

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

PharmaBlock Sciences Nanjing Inc
Common Shares Outstanding Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Common Shares Outstanding CAGR 3Y CAGR 5Y CAGR 10Y
PharmaBlock Sciences Nanjing Inc
SZSE:300725
Common Shares Outstanding
ÂĄ198.8m
CAGR 3-Years
0%
CAGR 5-Years
1%
CAGR 10-Years
N/A
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Common Shares Outstanding
ÂĄ5.9B
CAGR 3-Years
0%
CAGR 5-Years
3%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Common Shares Outstanding
ÂĄ603.3m
CAGR 3-Years
0%
CAGR 5-Years
0%
CAGR 10-Years
0%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Common Shares Outstanding
ÂĄ6.4B
CAGR 3-Years
0%
CAGR 5-Years
0%
CAGR 10-Years
0%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Common Shares Outstanding
ÂĄ1.8B
CAGR 3-Years
0%
CAGR 5-Years
7%
CAGR 10-Years
6%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Common Shares Outstanding
ÂĄ401m
CAGR 3-Years
0%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

PharmaBlock Sciences Nanjing Inc
Glance View

Market Cap
7.1B CNY
Industry
Pharmaceuticals

PharmaBlock Sciences (Nanjing), Inc. engages in the innovation of chemistry products and services throughout the pharmaceutical research and development process. The company is headquartered in Nanjing, Jiangsu and currently employs 1,735 full-time employees. The company went IPO on 2017-11-10. The firm's primary products include aromatic heterocyclic drug molecular building blocks, common saturated alicyclic drug molecular building blocks, four-membered ring drug molecular building blocks and special saturated ring drug molecular building blocks. The firm is also involved in development, production and sales of pharmaceutical intermediates, and provides technical services related to the development and process production of pharmaceutical molecular building blocks.

Intrinsic Value
54.21 CNY
Undervaluation 34%
Intrinsic Value
Price

See Also

What is PharmaBlock Sciences Nanjing Inc's Common Shares Outstanding?
Common Shares Outstanding
198.8m CNY

Based on the financial report for Sep 30, 2024, PharmaBlock Sciences Nanjing Inc's Common Shares Outstanding amounts to 198.8m CNY.

What is PharmaBlock Sciences Nanjing Inc's Common Shares Outstanding growth rate?
Common Shares Outstanding CAGR 5Y
1%

Over the last year, the Common Shares Outstanding growth was 0%.

Back to Top